Free Trial

Moloney Securities Asset Management LLC Purchases 5,533 Shares of CVS Health Corporation (NYSE:CVS)

CVS Health logo with Medical background

Moloney Securities Asset Management LLC increased its stake in CVS Health Corporation (NYSE:CVS - Free Report) by 20.3% during the 1st quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 32,838 shares of the pharmacy operator's stock after buying an additional 5,533 shares during the period. Moloney Securities Asset Management LLC's holdings in CVS Health were worth $2,225,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds and other institutional investors also recently made changes to their positions in CVS. Banque Pictet & Cie SA bought a new position in CVS Health in the 1st quarter valued at approximately $217,000. Wealth Advisory Solutions LLC bought a new position in CVS Health in the 1st quarter valued at approximately $505,000. Axxcess Wealth Management LLC bought a new position in shares of CVS Health during the 1st quarter valued at $695,000. Rehmann Capital Advisory Group lifted its holdings in shares of CVS Health by 8.8% during the 1st quarter. Rehmann Capital Advisory Group now owns 20,427 shares of the pharmacy operator's stock valued at $1,384,000 after buying an additional 1,658 shares during the period. Finally, Slagle Financial LLC bought a new position in shares of CVS Health during the 1st quarter valued at $1,325,000. Hedge funds and other institutional investors own 80.66% of the company's stock.

CVS Health Price Performance

Shares of CVS Health stock traded down $1.08 during trading on Thursday, reaching $65.58. 6,326,674 shares of the stock traded hands, compared to its average volume of 10,798,099. The company has a market capitalization of $82.96 billion, a price-to-earnings ratio of 15.65, a P/E/G ratio of 0.95 and a beta of 0.57. The business has a fifty day simple moving average of $65.10 and a two-hundred day simple moving average of $62.08. The company has a debt-to-equity ratio of 0.77, a current ratio of 0.82 and a quick ratio of 0.63. CVS Health Corporation has a 52-week low of $43.56 and a 52-week high of $72.51.

CVS Health (NYSE:CVS - Get Free Report) last issued its quarterly earnings data on Thursday, May 1st. The pharmacy operator reported $2.25 earnings per share for the quarter, beating analysts' consensus estimates of $1.62 by $0.63. The firm had revenue of $94.59 billion during the quarter, compared to analyst estimates of $93.07 billion. CVS Health had a return on equity of 10.59% and a net margin of 1.39%. The business's quarterly revenue was up 7.0% compared to the same quarter last year. During the same quarter last year, the business posted $1.31 earnings per share. Sell-side analysts expect that CVS Health Corporation will post 5.89 EPS for the current year.

CVS Health Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Friday, August 1st. Investors of record on Tuesday, July 22nd will be issued a $0.665 dividend. This represents a $2.66 dividend on an annualized basis and a dividend yield of 4.06%. The ex-dividend date of this dividend is Tuesday, July 22nd. CVS Health's payout ratio is 63.48%.

Wall Street Analysts Forecast Growth

Several equities analysts have recently weighed in on the company. Robert W. Baird increased their price target on CVS Health from $51.00 to $71.00 and gave the company a "neutral" rating in a report on Tuesday, April 15th. Royal Bank Of Canada upped their price objective on CVS Health from $74.00 to $81.00 and gave the stock an "outperform" rating in a research note on Monday, May 5th. Morgan Stanley restated an "overweight" rating on shares of CVS Health in a research note on Tuesday, April 15th. Truist Financial upped their price objective on CVS Health from $82.00 to $84.00 and gave the stock a "buy" rating in a research note on Monday, May 12th. Finally, Wall Street Zen upgraded CVS Health from a "hold" rating to a "buy" rating in a research note on Friday, May 9th. Two research analysts have rated the stock with a hold rating, eighteen have given a buy rating and one has given a strong buy rating to the company's stock. Based on data from MarketBeat, CVS Health has an average rating of "Moderate Buy" and an average target price of $75.06.

Get Our Latest Stock Report on CVS

Insider Activity at CVS Health

In other CVS Health news, Director Guy P. Sansone purchased 1,570 shares of the stock in a transaction that occurred on Thursday, June 5th. The stock was purchased at an average price of $63.70 per share, with a total value of $100,009.00. Following the acquisition, the director owned 12,007 shares in the company, valued at approximately $764,845.90. The trade was a 15.04% increase in their ownership of the stock. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Insiders own 1.22% of the company's stock.

CVS Health Profile

(Free Report)

CVS Health Corporation provides health solutions in the United States. It operates through Health Care Benefits, Health Services, and Pharmacy & Consumer Wellness segments. The Health Care Benefits segment offers traditional, voluntary, and consumer-directed health insurance products and related services.

Read More

Institutional Ownership by Quarter for CVS Health (NYSE:CVS)

Should You Invest $1,000 in CVS Health Right Now?

Before you consider CVS Health, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and CVS Health wasn't on the list.

While CVS Health currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

Elon Musk's Next Move Cover

Explore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Don’t Miss These Top 3 Defense Stocks Set To Gain
Triple-Digit Gains: These 4 Nuclear Stocks Have Even More Upside Ahead
3 Made in America Stocks Under $20 You Need to See!

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines